Treatment options in insulin resistance obesity-related acanthosis nigricans

Annals of Pharmacotherapy

Volumn 42, Issue 7-8, 2008, Pages 1090-1094

  Romo, Anthony ^a   Benavides, Sandra ^b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Acanthosis nigricans; Adolescents; Dermatology; Insulin resistance; Obesity

Indexed keywords

CALCIPOTRIOL; CORTICOSTEROID; GLUCOSE; INSULIN; METFORMIN; OCTREOTIDE; RETINOIC ACID; ROSIGLITAZONE; VITAMIN D DERIVATIVE;

ACANTHOSIS NIGRICANS; BODY WEIGHT; CLINICAL TRIAL; DIET THERAPY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE OBESITY RELATED ACANTHOSIS NIGRICANS; INSULIN RESPONSE; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; TEST MEAL; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACANTHOSIS NIGRICANS; ADOLESCENT; ADULT; CALCITRIOL; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; OBESITY; OCTREOTIDE; RETINOIDS; THIAZOLIDINEDIONES; VITAMIN D;

EID: 48249147764     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K446     Document Type: Review

References (22)

1. Hermanns-Le T, Scheen A, Pierard GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol 2004;5:199-203.
2. Stuart CA, Driscoll MS, Lundquist KF, Gilkison CR, Shaheb S, Smith MM. Acanthosis nigricans. J Basic Clin Physiol Pharmacol 1998;9:407-18.
3. Rendon MI, Cruz PD Jr, Sontheimer RD, Bergstresser PR. Acanthosis nigricans: a cutaneous marker of tissue resistance to insulin. J Am Acad Dermatol 1989;21:461-9.
4. Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol 2002;147:1096-101.
5. Brickman WJ, Binns HJ, Jovanovic BD, Kolesky S, Mancini AJ, Metzger BE. Acanthosis nigricans: a common finding in overweight youth. Pediatr Dermatol 2007;24:601-6.
6. Kuroki R, Sadamoto Y, Imamura M, et al. Acanthosis nigricans with severe obesity, insulin resistance and hypothyroidism: improvement by diet control. Dermatology 1999;198:164-6.
7. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-9.
8. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001;56:265-94.
9. Bellot-Rojas P, Posadas-Sanchez R, Caracas-Portilla N, et al. Comparison of metformin versus rosiglitazone in patients with acanthosis nigricans: a pilot study. J Drugs Dermatol 2006;5:884-9.
10. Tankova T, Koev D, Dakovska L, Kirilov G. Therapeutic approach in insulin resistance with acanthosis nigricans. Int J Clin Pract 2002;56:578-81.
11. Hermanns-Le T, Hermanns JF, Pierard GE. Juvenile acanthosis nigricans and insulin resistance. Pediatr Dermatol 2002;19:12-4.
12. Lee PJ, Cranston I, Amiel SA, O'Rahilly S, Green AA. Effect of metformin on glucose disposal and hyperinsulinaemia in a 14-year-old boy with acanthosis nigricans. Horm Res 1997;48:88-92.
13. Hsu WH, Xiang HD, Rajan AS, Kunze DL, Boyd AE 3rd. Somatostatin inhibits insulin secretion by a G-protein-mediated decrease in Ca2+ entry through voltage-dependent Ca2+ channels in the beta cell. J Biol Chem 1991;266:837-43.
14. Lunetta M, Di Mauro M, Le Moli R, Burrafato S. Long-term octreotide treatment reduced hyperinsulinemia, excess body weight and skin lesions in severe obesity with acanthosis nigricans. J Endocrinol Invest 1996;19:699-703.
15. Blobstein SH. Topical therapy with tretinoin and ammonium lactate for acanthosis nigricans associated with obesity. Cutis 2003;71:33-4.
16. Inamadar AC, Palit A. Generalized acanthosis nigricans in childhood. Pediatr Dermatol 2004;21:277-9.
17. Gupta AK, Browne M, Bluhm R. Nonpsoriatic uses of calcipotriol. J Cutan Med Surg 2002;6:442-8.
18. Berger BJ, Gross PR. Another use for tretinoin - pseudoacanthosis nigricans. Arch Dermatol 1973;108:133-4.
19. Binderup L, Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 1988;37:889-95.
20. de Jong EM, van de Kerkhof PC. Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long-term treatment with the vitamin D3 analogue MC903: modulations and interrelations. Br J Dermatol 1991;124:221-9.
21. Ortonne JP. Retinoid therapy of pigmentary disorders. Dermatol Ther 2006;19:280-8.
22. Burke JP, Hale DE, Hazuda HP, Stern MP. A quantitative scale of acanthosis nigricans. Diabetes Care 1999;22:1655-9.